Summit Therapeutics Inc. filed a prospectus supplement to its automatic shelf registration statement on Form S-3 for the potential issuance of common stock. The filing includes a legal opinion from Baker & Hostetler LLP regarding the legality of the shares being offered.
Summit Therapeutics entered into a securities purchase agreement with AstraZeneca for a $2.0 billion private placement of newly designated Class A Convertible Preferred Stock. The preferred shares are priced at a common stock equivalent of $18.3561 per share and will be used to support the development of ivonescimab, including new clinical collaborations with AstraZeneca's oncology portfolio.
Value
$2B
Counterparty
AstraZeneca Holdings B.V.
“This significant investment, as well as the collaboration, is a powerful validation of the potential of ivonescimab. We are proud to welcome AstraZeneca as a strategic investor as we continue to work with purposeful urgency to make a significant difference for patients with cancer by improving outcomes.”
Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics
“The developments announced today with AstraZeneca open an exciting new chapter in the advancement of ivonescimab. With a growing body of evidence supporting ivonescimab’s differentiated PD-1 / VEGF bispecific approach, we look forward to further broadening the development plan of ivonescimab and initiating new clinical trials exploring the potential to combine ivonescimab with promising novel anti-cancer compounds, including ADCs, to bring together complementary approaches to tumor-cell killing, antitumor immunity, and the tumor microenvironment.”
Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics